Imatinib and Beyond – Targeting Activated Tyrosine Kinases in Myeloproliferative Disorders

Publisher： Karger

E-ISSN： 2296-5262|35|1|34-41

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.1, 2012-01, pp. : 34-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Changing Concepts of Diagnostic Criteria of Myeloproliferative Disorders and the Molecular Etiology and Classification of Myeloproliferative Neoplasms: From Dameshek 1950 to Vainchenker 2005 and Beyond

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-08 ,pp. : 36-51

Karger

Access to resources Recommend Favorite

Myeloproliferative disorders in older people

By  

Reviews in Clinical Gerontology, Vol. 22, Iss. 2, 2012-05 ,pp. : 108-118

Cambridge University Press

Access to resources Recommend Favorite

Targeting Protein Kinases for Tumor Therapy

By  

Oncology Research and Treatment, Vol. 24, Iss. 4, 2001-09 ,pp. : 346-355

Karger

Access to resources Recommend Favorite

Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 87-101

Bentham Science Publishers

Access to resources Recommend Favorite

Complete Response of Myeloid Sarcoma with FIP1L1-PDGFRA-Associated Myeloproliferative Neoplasms to Imatinib Mesylate Monotherapy

By  

Acta Haematologica, Vol. 128, Iss. 2, 2012-06 ,pp. : 83-87

Karger

Access to resources Recommend Favorite